PTX Media related, page-690

Hey, Stirrer, my take is that perhaps CellPryme-A is very much now interwoven with our agreement with Therno Fisher. If I am right and it forms part of the manufacturing process and, more specifically, the cell programming stage of activation and non-viral transfection, then both companies would want to keep information pertaining to CP-A out of earshot of the industry for as long as possible. Patience and trust is all that is required. A couple of webinars ago, Steve stated that he was getting pretty tired of having to fend off questions about what CP-A is... so I think investors need to respect his position and, more importantly, respect his judgement on this matter. But it doesn't mean we can't try and nut it out here until such time as its disclosed.

Btw, its likely that Steve even told the presenter to ignore any questions on the subject of CP-A. Don't let it frustrate you. The fact that TFS and PTX want to keep it quiet longer surely is testament to the potential to ground-breaking calibre it could be representing!

This leads me to something that has been on my mind for a while now. I've been getting the sneaking suspicion that there is a lot of overlap with our two platforms OmniCAR and CellPryme. Of course, the overall synergy is immediately recognisable... and, according to the claims and some of the data we have been privy to, there is some duplicity of benefits achieved. I just wonder how much or many of the benefits achieved are attributable to OmniCAR alone? At what stage of our pre-clinical studies were standard T-cells used, CP-M and CP-A cells introduced into the OmniCAR R&D since last year? The term "switchability" was mentioned by Peter Marks of the FDA in the video Cosmo shared. The comment was in context of cell manufacturing, which is interesting.

Whilst I am 100% convinced that our two platforms can stand alone as independent platforms and have their own unique and universal benefits, it's becoming obvious that the two combined could produce a formidable system. If CP-A is a standout alternative to viral-vectoring, then its highly likely too that the system TFS and PTX intend designing will make provision for "inserts" (as Peter Marks mentions). Such "inserts" will allow new innovations and interventions to be introduced into the cell manufacturing system (substituting antiquated methodology) as the world of biotech and PTX evolve. This partnership with TFS could be the company-making piece of the jigsaw around which all the other pieces just click into place year after year!!!